324763-46-4

Basic information

• Product Name: 5(S)-[1(S)-Azido-3(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl]-3(S)-isopropyldihydrofuran-2-one
• Synonyms: 5(S)-[1(S)-Azido-3(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl]-3(S)-isopropyldihydrofuran-2-one;aliskireninterMediatebearing;2(3H)-Furanone, 5-[(1S,3S)-1-azido-3-[[4-Methoxy-3-(3-Methoxypropoxy)phenyl]Methyl]-4-Methylpentyl]dihydro-3-(1-Methylethyl)-, (3S,5S)-;2(3H)-Furanone, 5-[(1S,3S)-1-azido-3-[[4-Methoxy-3-(3-Methoxypropoxy)phenyl]Methyl]-4-Methylpentyl]d;(3S,5S)-5-{(1S,3S)-1-azido-3-[4-Methoxy-3-(3-Methoxypropoxy)benzyl]-4-Methylpentyl}-3-(1-Methylethyl)dihydrofuran-2(3H)-one;2(3H)-Furanone, 5-[(1S,3S)-1-azido-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpe
• CAS NO: 324763-46-4
• Molecular Formula: C₂₅H₃₉N₃O₅
• Molecular Weight: 461.6
• Mol File: 324763-46-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 1.19g/cm3 at 20℃
• Vapor Pressure: 0Pa at 20℃
• Storage Temp.: Amber Vial, -20°C Freezer, Under Inert Atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 5(S)-[1(S)-Azido-3(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl]-3(S)-isopropyldihydrofuran-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5(S)-[1(S)-Azido-3(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl]-3(S)-isopropyldihydrofuran-2-one(324763-46-4)
• EPA Substance Registry System: 5(S)-[1(S)-Azido-3(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl]-3(S)-isopropyldihydrofuran-2-one(324763-46-4)

Safety Data

• Hazardous Substances Data: 324763-46-4(Hazardous Substances Data)

Usage

Description

5(S)-[1(S)-Azido-3(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl]-3(S)-isopropyldihydrofuran-2-one is a complex organic compound characterized by its unique molecular structure and chemical properties. It is a yellow solid that serves as an intermediate in the synthesis of various pharmaceutical compounds.

Uses

Used in Pharmaceutical Industry:
5(S)-[1(S)-Azido-3(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl]-3(S)-isopropyldihydrofuran-2-one is used as an intermediate in the preparation of orally active renin inhibitor Aliskiren (A536000) for the treatment of hypertension. Its unique chemical structure allows for the development of effective and targeted therapies for cardiovascular diseases.
As a key intermediate in the synthesis of Aliskiren, this compound plays a crucial role in the pharmaceutical industry, contributing to the development of innovative treatments for hypertension and other related conditions. Its chemical properties and structural features make it a valuable component in the design and synthesis of new drugs with improved efficacy and safety profiles.

InChI:InChI=1/C25H39N3O5/c1-16(2)19(14-21(27-28-26)23-15-20(17(3)4)25(29)33-23)12-18-8-9-22(31-6)24(13-18)32-11-7-10-30-5/h8-9,13,16-17,19-21,23H,7,10-12,14-15H2,1-6H3/t19-,20-,21-,23-/m0/s1

Upstream product

• 325740-68-9 Methanesulfonic acid (1R,3S)-1-((2S,4S)-4-isopropyl-5-oxo-tetrahydro-furan-2-yl)-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl ester 
• 387353-75-5 4-Bromo-benzenesulfonic acid (1R,3S)-1-((2S,4S)-4-isopropyl-5-oxo-tetrahydro-furan-2-yl)-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl ester 
• 145589-03-3 (S)-4-benzyl-3-(3-methylbutanoyl)oxazolidin-2-one 
• 191152-27-9 (3S,5S)-5-Hydroxymethyl-3-isopropyl-dihydro-furan-2-one 
• 191152-26-8 (3S,5S)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-3-isopropyl-dihydro-furan-2-one 
• 192060-34-7 N-[(1S,2S)-2-hydroxy-1-methyl-2-phenylethyl]-3-N-dimethylbutyramide 
• 240821-65-2 (4S)-3-[(2S)-2-(1-methylethyl)-1-oxopent-4-en-1-yl]-4-(phenylmethyl)oxazolidin-2-one 
• 325740-55-4 (S)-5-Hydroxymethyl-3-isopropyl-dihydro-furan-2-one 
• 325740-56-5 (S)-4-Isopropyl-5-oxo-tetrahydro-furan-2-carbonyl chloride 
• 325740-59-8 tetrahydro-4-isopropyl-5-oxofuran-2-carboxylic acid 
• 325740-60-1 tetrahydro-4-isopropyl-5-oxofuran-2-carbonyl chloride 
• 172900-75-3 4-methoxy-3-(3-methoxypropoxy)benzaldehyde 
• 325740-58-7 (2S,4S)-4-Isopropyl-5-oxo-tetrahydro-furan-2-carboxylic acid benzyl ester 
• 324763-36-2 (E)-3-[4-Methoxy-3-(3-methoxy-propoxy)-phenyl]-acrylic acid 

Downstream Products

• 324763-47-5 (2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide 
• 890796-80-2 N-phenyl-5(S)-azido-4(S)-hydroxy-2(S)-isopropyl-7(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide 
• 173334-57-1 (2S,4S,5S,7S)-5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide 
• 909406-55-9 5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanoic acid (1-methylpiperidin-4-yl)amide 
• 890775-34-5 N-(pyridine-4-yl)-(2S,4S,5S,7S)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide 
• 1132671-96-5 (2S,4S,5S,7S)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid [3(R)- and 3(S)-(tetrahydro-furan-3-ylmethyl)]-amide 
• 1132671-64-7 (2S,4S,5S,7S)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (tetrahydro-pyran-2-ylmethyl)-amide 
• 853273-54-8 (2S,4S,5S,7S)-5-azido-4-(tert-butyl-dimethyl-silanyloxy)-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid 
• 1373444-03-1 C₃₀H₄₉N₅O₅ 
• 866030-35-5 tert-butyl {(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-3-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl}carbamate 
• 900811-48-5 3(S)-isopropyl-5(S)-{1(S)-amino-3(S)-isopropyl-4-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-butyl}-tetrahydrofuran-2-one 
• 173338-07-3 tert-butyl (3S,5S,6S,8S)-8-(3-amino-2,2-dimethyl-3-oxopropylcarbamoyl)-6-hydroxy-3-(4-methoxy-3-(3-methoxypropoxy)benzyl)-2,9-dimethyldecan-5-ylcarbamate 

Relevant articles and documents

A aliskiren or its salt separation and analysis method

The invention relates to a separation analysis method using polysaccharide derivative-bonded and coated silica as a stationary phase and an organic solvent as a mobile phase for separation analysis of aliskiren and isomers thereof, effective separation of the aliskiren and isomers thereof can be realized, and the separation analysis method has the important meaning to the product quality control.

SYNTHESIS OF ALISKIREN

The present invention provides novel process for the preparation of renin inhibitor Aliskiren or its derivatives, and its pharmaceutically acceptable salts. The present invention also provides novel intermediates used in the preparation of Aliskiren.

PROCESS FOR THE PREPARATION OF SUBSTITUTED OCTANOYL AMIDES

Compounds of formula (XII), are simultaneously halogenated in the 5 position and hydroxylated in the 4 position under lactonization, the halolactone is reacted with an amine to form a carboxamide, the halogen is replaced with azide, if necessary after the introduction of a hydroxy protecting group, the resulting azide is converted to a lactone, the lactone is amidated and then the azide converted to the amine group, in order to obtain compounds of formula (I) or a salt thereof.